Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04171492 · ClinicalTrials.gov registry record
Nodify XL2 Classifier Clinical Utility Study in Low to Moderate Risk Lung Nodules
A clinical trial of Non-small Cell Carcinoma and Nodule Solitary Pulmonary, sponsored by Biodesix.
- Active
- Registry status
- 2,000
- Enrollment target
- 20
- Study locations
NCT04171492 is a study of Non-small Cell Carcinoma and Nodule Solitary Pulmonary that is active but no longer recruiting, run by Biodesix. The registered enrollment target is 2,000 participants, above the 334-participant average among 5 other Non-small Cell Carcinoma trials with a reported enrollment target (499% higher). The trial reports 20 study locations across 13 states.
The verdict
NCT04171492, a study of Non-small Cell Carcinoma and Nodule Solitary Pulmonary, is active but no longer recruiting, sponsored by Biodesix.
- ACTIVE NOT RECRUITING
- Registry status
- 2,000 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study evaluates the how addition of the Nodify XL2 test result impacts the clinical management of newly identified solid lung nodules assessed as low to moderate risk of cancer.
Conditions Studied
Study Locations (20)
North Carolina
- The University of North Carolina - Chapel Hill
- Duke University - Durham
- Southeastern Research Center - Winston-Salem
South Carolina
- Ralph H Johnson VA Medical Center - Charleston
- Medical University of South Carolina - Charleston
- Prisma Health - Greenville
Connecticut
- Massachusetts General Hospital - Boston
- Beth Israel Deaconess - Boston
New York
- Mount Sinai Health System - New York
- Northwell Health - New York
Ohio
- Cleveland Clinic - Cleveland
- The Ohio State University - Coulmbus
Colorado
- University of Colorado - Aurora
District of Columbia
- MedStar - Washington D.C.
Indiana
- Indiana University - Indianapolis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,000 participants |
| Start Date | 2020-12-18 |
| Est. Completion | 2026-12 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04171492
The ClinicalTrials.gov registry entry for NCT04171492 describes a study currently listed as active not recruiting, categorized as an unspecified phase. The registered enrollment target is 2,000 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 334-participant average among 5 other Non-small Cell Carcinoma trials with a reported enrollment target (499% higher). The listed sponsor is Biodesix, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Non-small Cell Carcinoma appearing as the primary indexed condition, and to 0 interventions.
NCT04171492 reports 20 study locations spanning 13 distinct geographic areas - top geographies include North Carolina, South Carolina, Connecticut.
Frequently Asked Questions
What is clinical trial NCT04171492 about?
NCT04171492 is a clinical study titled "Nodify XL2 Classifier Clinical Utility Study in Low to Moderate Risk Lung Nodules". This study evaluates the how addition of the Nodify XL2 test result impacts the clinical management of newly identified solid lung nodules assessed as low to moderate risk of cancer.
What is the current status of trial NCT04171492?
This trial is currently active not recruiting. The enrollment target is 2,000 participants. The study started on 2020-12-18. Estimated completion is 2026-12.
What conditions does trial NCT04171492 study?
This clinical trial studies the following conditions: Non-small Cell Carcinoma, Nodule Solitary Pulmonary.
Who is sponsoring clinical trial NCT04171492?
This trial is sponsored by Biodesix, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04171492 being conducted?
This trial has 20 study locations across Colorado, Connecticut, District of Columbia, Indiana, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Non-small Cell Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)
RECRUITING · Phase 3
-
A Study of Targeted Radiation Therapy in People With Non-Small Cell Lung Cancer (NSCLC)
RECRUITING · Phase 2
-
A Basket Study of Customized Autologous TCR-T Cell Therapies in Patients With Locally Advanced (Unresectable) or Metastatic Solid Tumors
ACTIVE NOT RECRUITING · Phase 1
-
Safety and Efficacy of Zimberelimab (AB122) in Combination With Domvanalimab (AB154) and Etrumadenant (AB928) in Patients With Previously Treated Non-Small Cell Lung Cancer
ACTIVE NOT RECRUITING · Phase 2
-
Vaccine Treatment for Advanced Non-Small Cell Lung Cancer
COMPLETED · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.